Enumera Molecular, founded in Ann Arbor, MI, is a life science tools company dedicated to transforming clinical molecular testing. Their core mission is to develop scalable biomolecule assessment platforms that enable low-cost, rapid clinical liquid biopsy tests. Enumera Molecular offers the EnumeraPlex platform, a single-molecule counting technology designed to simplify complex, high-analyte molecular testing. This platform provides high-performance pan-omic detection without PCR bias and eliminates the need for bioinformatics analysis, making it accessible and efficient for laboratory use.

Notable figures associated with Enumera Molecular include key scientists and industry experts who have contributed to the development of their innovative technologies. The company has attracted significant investment from venture capital firms specializing in life sciences. Enumera Molecular's achievements include the successful deployment of their EnumeraPlex platform in various clinical settings, demonstrating its potential to revolutionize molecular diagnostics. Their impact lies in making advanced molecular testing more accessible, cost-effective, and user-friendly, thereby enhancing the precision and speed of clinical diagnostics.